Filtering by Category: diagnostics

Multi-Marker Protein Panel Detects Ovarian Cancer Up To Two Years Earlier

Researchers at Queens University Belfast have published findings where a multi-marker panel of 4 proteins (CA125, phosphatidylcholine-sterol aceltransferase, vitamin K-dependent protein Z, and CRP) has the potential to diagnose epithelial ovarian cancer (EOC) one to two years earlier than current methods.

The SpotProfiler is a prime candidate to translate this type of research finding into an easily accessible medical tool for physicians with its multi-marker protein microarray approach.

Categories: diagnostics

Published on by Winnie So. Source.

Tabletop blood count developer Sight raises $27.8M in series C round

Sight Diagnostics received the CE Mark last year for its OLO system, which uses digital microscopy to visually analyze cell types by size, shape, count and morphology, from a few drops of blood during a single office visit. The technology has been used to screen over 600,000 samples for malaria infections and will now be adding complete blood count testing to its system. Sight Diagnostics has raised US$27.8 million to continue its global commercial expansion, fund regulatory efforts and support its research and development.

Categories: diagnostics, finance

Published on by Winnie So. Source.

CellMax Life blood test study detects precancer colorectal polyps with 90% accuracy

CellMax Life’s CMx platform filters out and counts precancer and cancer cells in the bloodstream. It’s FirstSightCRC test was able to detect the small, precancerous colon polyps known as adenomas with close to 90% accuracy. The increases in cell counts also correlates with increases in disease severity. This is a highly sensitive noninvasive testing option for precancer instead of a colonoscopy.

Categories: diagnostics

Published on by Winnie So. Source.

Contextual Genomics launches new liquid biopsy test and updated solid tumor panel

Contextual Genomics provides assays for detecting genomic mutations in blood and solid tumours. It has released a new version of its Find It solid tumour panel, while its new Follow It panel screens for the same mutations in cell-free circulating tumour DNA found in blood plasma. Follow It can be used to monitor tumour burden, treatment resistance and disease progression.

Categories: diagnostics

Published on by Winnie So. Source.

Proteome blood test developer Seer emerges with $36M in funding

Liquid biopsy company, Seer, has received $36 million in funding to develop early-warning tests for cancer and neurological diseases. It uses nanotechnology, protein chemistry and machine learning algorithms to profile a broad array of the body’s proteins and generate insights into the progression of diseases at the population level. Seer hopes to collaborate with industry partners to develop new products using this system.

Categories: diagnostics

Published on by Winnie So. Source.